
    
      -  Experimental design: Phase III, open-label, non-randomised, multi-centric,
           single-country study with a single group.

        -  Duration of the study: The intended duration of the study will be approximately 3 months
           per subject.

        -  Treatment group and vaccination schedule: All subjects will receive three doses of the
           vaccine at 6, 10 and 14 weeks of age.

             -  DTPa-IPV/Hib Group: Subjects who will receive DTPa-IPV/Hib vaccine
                (Infanrix-IPV/Hib).

      Other routine registered childhood vaccinations as part of National Immunisation Programme
      are permitted. Information regarding vaccine administered since birth until study completion
      will be collected and documented.
    
  